Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer

Reviewing deaths within 30 days of systemic anti-cancer therapy: Driving quality in a regional chemotherapy service.

(2017) Caroline Forde et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Delayed Adjuvant Chemotherapy With Survival After Lung Cancer Surgery

(2017) Michelle C. Salazar et al.   JAMA Oncology

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

(2016) Corey J Langer et al.   LANCET ONCOLOGY

Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

(2015) Karen Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data

(2014)   LANCET

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

(2013) Chee Khoon Lee et al.   JNCI-Journal of the National Cancer Institute

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study

(2012) M. Kreuter et al.   ANNALS OF ONCOLOGY

Time to adjuvant chemotherapy and survival in non-small cell lung cancer

(2012) Christopher M. Booth et al.   CANCER

Re-evaluation of the prognostic value of visceral pleura invasion in Stage IB non-small cell lung cancer using the prospective multicenter ACOSOG Z0030 trial data set

(2012) Juan J. Fibla et al.   LUNG CANCER

Impact of visceral pleural invasion on the survival of patients with non-small cell lung cancer

(2012) Yujin Kudo et al.   LUNG CANCER

Impact of Angiolymphatic and Pleural Invasion on Surgical Outcomes for Stage I Non-Small Cell Lung Cancer

(2011) Matthew J. Schuchert et al.   ANNALS OF THORACIC SURGERY

Surgery With or Without Preoperative Paclitaxel and Carboplatin in Early-Stage Non–Small-Cell Lung Cancer: Southwest Oncology Group Trial S9900, an Intergroup, Randomized, Phase III Trial

(2010) Katherine M.W. Pisters et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non–Small-Cell Lung Cancer

(2010) Enriqueta Felip et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations

(2010) Yelena Y. Janjigian et al.   Journal of Thoracic Oncology

The New Lung Cancer Staging System

(2009) Frank C. Detterbeck et al.   CHEST

Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non–Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10

(2009) Charles A. Butts et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung Cancer

(2009) Rodrigo Arriagada et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group

(2008) Jean-Pierre Pignon et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non–Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

(2008) Gary M. Strauss et al.   JOURNAL OF CLINICAL ONCOLOGY